芪苈强心胶囊对射血分数降低的心力衰竭患者CTGF、TGF-β_(1)水平的影响  

Effect of Qili Qiangxin Capsule on CTGF and TGF-β_(1) levels in patients with heart failure with reduced ejection fraction

作　　者：张亚帅 刘沛 ZHANG Yashuai;LIU Pei(Department of Internal Medicine,Puyang Guangci Hospital,Puyang Henan 457000,China)

机构地区：[1]濮阳广慈医院内科,河南濮阳457000

出　　处：《实用心电与临床诊疗》2025年第1期94-97,102,共5页PRACTICAL ELECTROCARDIOLOGY AND CLINICAL TREATMENT

摘　　要：目的探讨基于脉络学说理论指导研制的芪苈强心胶囊在射血分数降低的心力衰竭(heart failure with reduced ejection fraction,HFrEF)患者中的应用效果。方法按照随机数字表法将110例HFrEF患者分为两组:对照组(55例)口服沙库巴曲缬沙坦治疗;观察组(55例)采用口服沙库巴曲缬沙坦和芪苈强心胶囊治疗,两组均持续治疗8周。比较两组的临床疗效,以及治疗前后的中医证候积分、心功能指标、心肌纤维化指标[结缔组织生长因子(connective tissue growth factor,CTGF)、转化生长因子-β_(1)(transforming growth factor-β_(1),TGF-β_(1))]、氨基末端脑钠肽前体(NT-proBNP)和药物不良反应发生率。结果观察组总有效率明显高于对照组(90.91%vs.76.36%,P<0.05)。治疗后观察组心功能各项指标均明显优于对照组(均P<0.05),而心肌纤维化指标、NT-proBNP以及中医证候积分均明显低于对照组(均P<0.05)。两组药物不良反应发生率间的差异无统计学意义(P>0.05)。结论HFrEF患者在沙库巴曲缬沙坦基础上加用芪苈强心胶囊治疗效果显著,有利于减少心肌纤维化和心肌细胞的凋亡,保护患者心功能,改善中医证候积分,且患者耐受性良好,具有较高的安全性。Objective To explore the application effect of Qili Qiangxin Capsule developed based on the pulsecollateral theory in patients with heart failure with reduced ejection fraction(HFrEF).Methods A total of 110 patients with HFrEF were randomly divided into two groups by using the random number table method.Among them,the control group(55 cases)was treated with oral sacubitril/valsartan,while the observation group(55 cases)was treated with oral sacubitril/valsartan and Qili Qiangxin Capsule.Both groups were continuously treated for 8 weeks.The clinical efficacy,and incidences of adverse drug reactions were compared between the two groups,as well as the traditional Chinese medicine syndrome score,cardiac function indicators,myocardial fibrosis indicators[connective tissue growth factor(CTGF)and transforming growth factor-β_(1)(TGF-β_(1))],and N-terminal pro-brain natriuretic peptide(NT-proBNP)before and after treatment.Results The total effective rate of the observation group was significantly higher than that of the control group(90.91%vs.76.36%,P<0.05).After treatment,each cardiac function indicator in the observation group was significantly better than that in the control group(P<0.05),while the myocardial fibrosis indicators,NT-proBNP,and traditional Chinese medicine syndrome score in the observation group were all significantly lower than those in the control group(all P<0.05).There was no statistically significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).Conclusion The addition of Qili Qiangxin Capsule to sacubitril/valsartan in HFrEF patients achieves significant therapeutic effects,which are beneficial for reducing myocardial fibrosis and apoptosis of myocardial cells,protecting patientscardiac function,improving traditional Chinese medicine syndrome scores,with good patient tolerability and high safety.

关 键 词：射血分数降低的心力衰竭 芪苈强心胶囊 沙库巴曲缬沙坦 心功能 结缔组织生长因子 转化生长因子 

分 类 号：R541.6[医药卫生—心血管疾病]